JP7720833B2 - Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法 - Google Patents

Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法

Info

Publication number
JP7720833B2
JP7720833B2 JP2022524112A JP2022524112A JP7720833B2 JP 7720833 B2 JP7720833 B2 JP 7720833B2 JP 2022524112 A JP2022524112 A JP 2022524112A JP 2022524112 A JP2022524112 A JP 2022524112A JP 7720833 B2 JP7720833 B2 JP 7720833B2
Authority
JP
Japan
Prior art keywords
alkyl
group
aryl
cycloalkyl
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022524112A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021087093A5 (https=
JP2023500611A5 (https=
JP2023500611A (ja
Inventor
ナサナエル エス． グレイ，
フー リウ，
ティンフー ジャン，
リン ハワード ジョーンズ，
ジャンウェイ チェ，
Original Assignee
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド filed Critical ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Publication of JP2023500611A publication Critical patent/JP2023500611A/ja
Publication of JPWO2021087093A5 publication Critical patent/JPWO2021087093A5/ja
Publication of JP2023500611A5 publication Critical patent/JP2023500611A5/ja
Application granted granted Critical
Publication of JP7720833B2 publication Critical patent/JP7720833B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022524112A 2019-10-30 2020-10-29 Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法 Active JP7720833B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962928139P 2019-10-30 2019-10-30
US62/928,139 2019-10-30
US202063035272P 2020-06-05 2020-06-05
US63/035,272 2020-06-05
US202063047411P 2020-07-02 2020-07-02
US63/047,411 2020-07-02
PCT/US2020/057930 WO2021087093A1 (en) 2019-10-30 2020-10-29 Small molecule degraders of helios and methods of use

Publications (4)

Publication Number Publication Date
JP2023500611A JP2023500611A (ja) 2023-01-10
JPWO2021087093A5 JPWO2021087093A5 (https=) 2023-10-30
JP2023500611A5 JP2023500611A5 (https=) 2023-10-30
JP7720833B2 true JP7720833B2 (ja) 2025-08-08

Family

ID=75715607

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524112A Active JP7720833B2 (ja) 2019-10-30 2020-10-29 Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法

Country Status (16)

Country Link
US (1) US20230002397A1 (https=)
EP (1) EP4051386A4 (https=)
JP (1) JP7720833B2 (https=)
KR (1) KR20220092920A (https=)
CN (1) CN114650868A (https=)
AU (1) AU2020374957A1 (https=)
BR (1) BR112022007867A2 (https=)
CA (1) CA3154942A1 (https=)
CL (1) CL2022001111A1 (https=)
CR (1) CR20220234A (https=)
DO (1) DOP2022000091A (https=)
IL (1) IL292173A (https=)
MX (1) MX2022005232A (https=)
PE (1) PE20221457A1 (https=)
PH (1) PH12022550980A1 (https=)
WO (1) WO2021087093A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220234A (es) * 2019-10-30 2022-07-19 Dana Farber Cancer Inst Inc Degradadores de moléculas pequeñas de helios y procedimientos de uso
AU2020387392B2 (en) 2019-11-19 2025-09-11 Bristol-Myers Squibb Company Compounds useful as inhibitors of Helios protein
US20230271940A1 (en) * 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
IL301690A (en) * 2020-10-16 2023-05-01 Dana Farber Cancer Inst Inc Piperidinyl small molecule degraders of helios and methods of use
EP4452415B1 (en) 2021-12-22 2026-02-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118401512A (zh) * 2021-12-24 2024-07-26 苏州开拓药业股份有限公司 一种具有酰亚胺骨架的多蛋白降解剂
CN116640122A (zh) * 2022-02-16 2023-08-25 苏州国匡医药科技有限公司 Ikzf2降解剂及包含其的药物组合物和用途
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
WO2023183540A1 (en) * 2022-03-25 2023-09-28 Regents Of The University Of Michigan Ikzf2 degraders and uses thereof
WO2023201012A1 (en) * 2022-04-15 2023-10-19 Regents Of The University Of Michigan Ikzf2 degraders and uses thereof
CN119013270A (zh) * 2022-04-29 2024-11-22 西藏海思科制药有限公司 一种含氮杂环衍生物及其组合物和药学上的应用
EP4570792A1 (en) * 2022-08-10 2025-06-18 Gluetacs Therapeutics (Shanghai) Co., Ltd. Compound based on isoindoline-substituted glutarimide backbone and use thereof
WO2024073871A1 (en) * 2022-10-04 2024-04-11 Biofront Ltd Gspt1 degraders, compositions comprising the degrader, and methods of using the same
JP2025537123A (ja) * 2022-11-11 2025-11-14 ニカング セラピューティクス， インコーポレイテッド ユビキチンプロテアソーム経路を介してサイクリン依存性キナーゼ２を分解するための２，５－置換ピリミジン誘導体を含有する二官能性化合物
WO2024109918A1 (zh) * 2022-11-24 2024-05-30 西藏海思科制药有限公司 一种gspt1降解剂及其在医药上的应用
WO2024222918A1 (zh) * 2023-04-28 2024-10-31 中国药科大学 一种苯并六元杂环类gspt1蛋白降解剂及其应用
WO2025011624A1 (en) * 2023-07-11 2025-01-16 Etern Biopharma (Shanghai) Co., Ltd. Bifunctional compounds for androgen receptor degradation and methods of use
CN121532386A (zh) * 2023-07-28 2026-02-13 杭州中美华东制药有限公司 具有蛋白降解作用的芳胺类化合物
WO2025097092A1 (en) * 2023-11-02 2025-05-08 Neomorph, Inc. Substituted 3-(5-(4-hydroxypiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and 3-(2-(4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6h-pyrrolo[3,4-b]pyridin-6-yl)piperidine-2,6-dione derivatives and uses thereof
WO2025245178A1 (en) * 2024-05-21 2025-11-27 Innovo Therapeutics, Inc. Pak4, cstf2, or cstf2t protein degraders, pharmaceutical compositions, and therapeutic applications

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019038717A1 (en) 2017-08-23 2019-02-28 Novartis Ag 3- (1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
WO2019079569A1 (en) 2017-10-18 2019-04-25 Novartis Ag COMPOSITIONS AND METHODS FOR SELECTIVE DEGRADATION OF A PROTEIN
JP2022520811A (ja) 2019-02-15 2022-04-01 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012268036B2 (en) * 2011-06-06 2017-04-06 THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF STATE OF THE DEPARTMENT OF VETERANS AFFAIRS Methods of inhibiting muscle atrophy
EP3924055B1 (en) * 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020168172A1 (en) * 2019-02-15 2020-08-20 Zamboni Chem Solutions Inc. Conjugate compounds for the degradation of raf
CR20220234A (es) * 2019-10-30 2022-07-19 Dana Farber Cancer Inst Inc Degradadores de moléculas pequeñas de helios y procedimientos de uso
KR20220147109A (ko) * 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
CN115916199A (zh) * 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
IL301690A (en) * 2020-10-16 2023-05-01 Dana Farber Cancer Inst Inc Piperidinyl small molecule degraders of helios and methods of use
CN117355299A (zh) * 2021-04-29 2024-01-05 尼奥莫夫公司 取代的2-(2,6-二氧代哌啶-3-基)-5-(1-哌啶-4-基)异吲哚啉-1,3-二酮衍生物及其用途
CA3209633A1 (en) * 2021-04-29 2022-11-03 Tinghu Zhang Phthalimido cereblon complex binders and transcription factor degraders and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019038717A1 (en) 2017-08-23 2019-02-28 Novartis Ag 3- (1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
WO2019079569A1 (en) 2017-10-18 2019-04-25 Novartis Ag COMPOSITIONS AND METHODS FOR SELECTIVE DEGRADATION OF A PROTEIN
JP2022520811A (ja) 2019-02-15 2022-04-01 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用

Also Published As

Publication number Publication date
DOP2022000091A (es) 2022-08-31
MX2022005232A (es) 2022-06-08
CR20220234A (es) 2022-07-19
CA3154942A1 (en) 2021-05-06
EP4051386A4 (en) 2024-05-22
CN114650868A (zh) 2022-06-21
JP2023500611A (ja) 2023-01-10
PH12022550980A1 (en) 2023-10-09
IL292173A (en) 2022-06-01
WO2021087093A1 (en) 2021-05-06
CL2022001111A1 (es) 2022-11-18
PE20221457A1 (es) 2022-09-21
EP4051386A1 (en) 2022-09-07
AU2020374957A1 (en) 2022-04-28
US20230002397A1 (en) 2023-01-05
BR112022007867A2 (pt) 2022-07-12
KR20220092920A (ko) 2022-07-04

Similar Documents

Publication Publication Date Title
JP7720833B2 (ja) Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法
CA3093405C (en) POLYBROMO-1 SMALL MOLECULE DEGRADING AGENTS (PBRM1)
US12234220B2 (en) Immunomodulatory compounds
KR20210098960A (ko) Helios의 소분자 분해제 및 사용 방법
JP2023545396A (ja) Ｈｅｌｉｏｓのピペリジニル低分子分解剤および使用方法
US20250066326A1 (en) Bcl6 degraders and uses thereof
JP7626721B2 (ja) 小分子標的ブロモ／アセチルタンパク質およびその使用
US20240376096A1 (en) Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
US20230192644A1 (en) Piperidine-2,6-diones as small molecule degraders of helios and methods of use
US20240308982A1 (en) Degraders of wild-type and mutant forms of lrrk2 and uses thereof
KR20230167009A (ko) Her2에 대한 강력하고 선택적인 억제제
US20240374737A1 (en) Erk5 degraders and uses thereof
CN116801878A (zh) Her2的有效和选择性抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250710

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250729

R150 Certificate of patent or registration of utility model

Ref document number: 7720833

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150